Retia Medical

Retia Medical is a commercial-stage medical device company offering non-invasive, software-based cardiac output (CO) monitoring systems. Its core technology, the Multi-Beat Analysis (MBA) algorithm, analyzes existing biosignals to provide accurate hemodynamic data without proprietary disposable sensors, addressing cost and scalability limitations of traditional monitors. With FDA-cleared products, installations in over 75 hospitals, and validation across 14 clinical studies, Retia is positioned to capitalize on the growing need for scalable hemodynamic management in perioperative and critical care settings. The company's model aligns with healthcare economics trends, such as the upcoming tie of acute kidney injury to reimbursement in 2027.

Multi-Beat Analysis (MBA™) algorithm: A software platform that transforms routine arterial blood pressure and ECG signals into reliable, continuous cardiac output and hemodynamic data without proprietary disposable sensors.

Retia competes with traditional invasive monitors (e.g., pulmonary artery catheters) and minimally invasive monitors that require proprietary disposable sensors (e.g., Edwards Lifesciences' FloTrac, Getinge's Pulseion). Its key differentiators are lower operational cost (no disposables), reliability in arrhythmia/shock, and software-driven scalability across the care continuum.